Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 2.550-2.650 for the period, compared to the consensus earnings per share estimate of 2.590. The company issued revenue guidance of $16.8 billion-$17.0 billion, compared to the consensus revenue estimate of $16.9 billion.

Teva Pharmaceutical Industries Trading Down 1.5%

Shares of TEVA stock opened at $32.03 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $32.91. The stock has a market capitalization of $36.73 billion, a P/E ratio of 53.38, a P/E/G ratio of 1.86 and a beta of 0.66. The firm’s 50 day moving average is $28.04 and its 200 day moving average is $21.60.

Analysts Set New Price Targets

Several analysts recently commented on TEVA shares. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Barclays began coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Buy” and an average target price of $33.67.

Insider Activity

In other news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 622,060 shares of company stock valued at $17,076,965. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva agreed with Royalty Pharma on up to $500 million of funding to accelerate development of its anti‑IL‑15 antibody TEV‑‘408 for vitiligo; emerging Phase 1b data reportedly support IL‑15 as a therapeutic target and Teva expects to share trial results during 2026. This is a major non‑dilutive financing and creates a clear clinical catalyst. Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
• Positive Sentiment: Truist raised its price target on TEVA to $36 from $32 and kept a Buy rating, citing continued strength in the affordable medicines theme — a supportive analyst view that can lift investor sentiment and valuation expectations. Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32
• Positive Sentiment: A Wall Street Zen upgrade to Strong‑Buy adds to positive analyst/quant sentiment and may attract momentum flows and new investors. Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to Strong-Buy at Wall Street Zen
• Positive Sentiment: Coverage noting high institutional ownership and recent weekly gains (stock was up about 3.4% last week) underscores demand from large holders and recent momentum that can support the share price going forward. Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) high institutional ownership speaks for itself as stock continues to impress, up 3.4% over last week
• Neutral Sentiment: Teva’s CEO Richard Francis will present at the J.P. Morgan Healthcare Conference on Jan. 13 to outline the “pivot to growth” strategy — this is an opportunity for management to provide updates, but impact depends on whether new financial or clinical detail is disclosed. Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TEVA. CIBC Private Wealth Group LLC boosted its stake in Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after purchasing an additional 540 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $234,000. Danske Bank A S purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $5,012,000. Advisory Services Network LLC boosted its position in shares of Teva Pharmaceutical Industries by 11.1% during the third quarter. Advisory Services Network LLC now owns 53,055 shares of the company’s stock worth $1,072,000 after acquiring an additional 5,318 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 5.2% during the third quarter. NewEdge Advisors LLC now owns 44,150 shares of the company’s stock worth $892,000 after acquiring an additional 2,180 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.